It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease.
作者信息
Geem Duke, Kugathasan Subra
机构信息
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
出版信息
Inflamm Bowel Dis. 2021 Jul 27;27(8):1361-1362. doi: 10.1093/ibd/izaa279.
Abstract
摘要
相似文献
1
It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2021 Jul 27;27(8):1361-1362. doi: 10.1093/ibd/izaa279.
2
Biologic drugs for inflammatory bowel disease.
Nihon Rinsho. 2017 Mar;75(3):403-407.
3
Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2019 Aug 20;25(9):1586-1593. doi: 10.1093/ibd/izz006.
4
Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
Aliment Pharmacol Ther. 2021 Jul;54(1):92-93. doi: 10.1111/apt.16387.
5
Safety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.
Inflamm Bowel Dis. 2020 Nov 19;26(12):e157-e158. doi: 10.1093/ibd/izaa182.
6
The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
J Med Econ. 2020 Oct;23(10):1102-1110. doi: 10.1080/13696998.2020.1791889. Epub 2020 Jul 23.
7
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
N Engl J Med. 2021 Sep 30;385(14):1302-1315. doi: 10.1056/NEJMra1907607.
8
Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2020 May 12;26(6):949-959. doi: 10.1093/ibd/izz244.
9
Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach.
Gastroenterol Clin North Am. 2014 Sep;43(3):425-40. doi: 10.1016/j.gtc.2014.05.004.
10
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study.
J Dig Dis. 2020 May;21(5):264-271. doi: 10.1111/1751-2980.12867. Epub 2020 Jun 11.
引用本文的文献
1
[Position paper of the Society for Paediatric Gastroenterology and Nutrition (GPGE) on the off-label use of biologics and signal inhibitors in children and adolescents with IBD that have already been approved for adults].
Z Gastroenterol. 2025 Mar;63(3):255-268. doi: 10.1055/a-2474-3104. Epub 2025 Feb 17.
2
Cytokine Profile in Predicting the Effectiveness of Advanced Therapy for Ulcerative Colitis: A Narrative Review.
Biomedicines. 2024 Apr 25;12(5):952. doi: 10.3390/biomedicines12050952.
3
Dual Biologic Therapy in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Retrospective Study.
Children (Basel). 2022 Dec 21;10(1):11. doi: 10.3390/children10010011.
4
Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature.
J Clin Med. 2022 Apr 3;11(7):2004. doi: 10.3390/jcm11072004.
5
Companion Diagnostics: State of the Art and New Regulations.
Biomark Insights. 2021 Oct 11;16:11772719211047763. doi: 10.1177/11772719211047763. eCollection 2021.
本文引用的文献
1
The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
Curr Gastroenterol Rep. 2020 Jun 15;22(8):36. doi: 10.1007/s11894-020-00773-3.
2
Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.
Paediatr Drugs. 2020 Aug;22(4):409-416. doi: 10.1007/s40272-020-00396-1.
3
Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center.
Clin Gastroenterol Hepatol. 2021 Mar;19(3):616-617. doi: 10.1016/j.cgh.2020.02.017. Epub 2020 Feb 14.
4
Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease.
Aliment Pharmacol Ther. 2019 Oct;50(8):966-967. doi: 10.1111/apt.15496.
5
Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
J Pediatr Gastroenterol Nutr. 2019 Jul;69(1):61-67. doi: 10.1097/MPG.0000000000002362.
6
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
Scand J Gastroenterol. 2019 Apr;54(4):407-413. doi: 10.1080/00365521.2019.1597159. Epub 2019 Apr 4.
7
Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
J Crohns Colitis. 2019 Apr 26;13(5):578-584. doi: 10.1093/ecco-jcc/jjy206.
8
Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
J Crohns Colitis. 2018 May 25;12(6):635-643. doi: 10.1093/ecco-jcc/jjy004.
9
Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2016 Oct;22(10):2425-31. doi: 10.1097/MIB.0000000000000918.
10
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.
Inflamm Bowel Dis. 2014 Apr;20(4):606-13. doi: 10.1097/MIB.0000000000000003.
Zotero 插件